{{Rsnum
|rsid=3924426
|Gene=SLCO3A1
|Chromosome=15
|position=91902643
|Orientation=plus
|GMAF=0.1001
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLCO3A1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 0.7 | 14.0 | 85.3
| JPT | 0.9 | 8.8 | 90.3
| YRI | 11.6 | 41.5 | 46.9
| ASW | 3.5 | 35.1 | 61.4
| CHB | 0.7 | 14.0 | 85.3
| CHD | 0.0 | 9.2 | 90.8
| GIH | 0.0 | 17.8 | 82.2
| LWK | 6.4 | 43.1 | 50.5
| MEX | 3.4 | 17.2 | 79.3
| MKK | 3.8 | 30.8 | 65.4
| TSI | 0.0 | 3.9 | 96.1
| HapMapRevision=28
}}

{{GWAS Summary
|SNP=rs3924426
|PubMedID=18521091
|Condition=Response to iloperidone treatment (QT prolongation)
|Gene=SLCO3A1
|Risk Allele=T
|pValue=2.00E-006
|OR=NA
|95CI=
}}

{{PharmGKB
|RSID=rs3924426
|Name_s=
|Gene_s=SLCO3A1
|Feature=
|Evidence=PubMed ID:18521091; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia (Initial Sample Size: 183 individuals; Replication Sample Size: NR; Risk Allele: rs3924426-T). This variant is associated with Response to iloperidone treatment (QT prolongation).
|Drugs=iloperidone
|Drug Classes=
|Diseases=Acquired Long QT Syndrome (aLQTS); congenital long QT syndrome; Long QT Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356588
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3924426
|overall_frequency_n=11
|overall_frequency_d=128
|overall_frequency=0.0859375
|n_genomes=7
|n_genomes_annotated=0
|n_haplomes=7
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}